Liraglutide and Semaglutide Improve Psoriasis Severity and Metabolic Markers in Cohort Studies
The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis
Abstract
Liraglutide and semaglutide, GLP-1 receptor agonists, improve psoriasis severity, metabolic parameters, and inflammatory markers, suggesting direct immunomodulatory effects beyond weight loss.